2-(methylamino)-N-(5-methylpyridin-2-yl)acetamide | 1019385-30-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(methylamino)-N-(5-methylpyridin-2-yl)acetamide
• CAS: 1019385-30-8
• 化学式: C₉H₁₃N₃O
• mdl: MFCD11128698
• 分子量: 179.22
• InChiKey: PREWFIYFJIZHFL-UHFFFAOYSA-N

物化性质

• 沸点：
  373.7±32.0 °C(Predicted)
• 密度：
  1.139±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  54
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] FUSED QUINOLINE COMPUNDS AS PI3K/MTOR INHIBITORS<br/>[FR] COMPOSÉS DE QUINOLÉINE FUSIONNÉS COMME INHIBITEURS DE PI3K/MTOR
  申请人：ADVENCHEN PHARMACEUTICALS LLC

  公开号：WO2017011363A1

  公开（公告）日：2017-01-19

  The present invention relates to the compounds of formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with cancers associated with protein kinases, to their use as medicaments for use in the production of inhibition of mTor, pi3k reducing effects in warm¬ blooded animals such as humans.

  本发明涉及公式I的化合物，其制备方法，含有其作为活性成分的药物组合物，用于治疗与蛋白激酶相关的癌症疾病状态的方法，以及作为药物用于在温血动物（如人类）中产生对mTor、pi3k的抑制作用的用途。
• Fused quinoline compounds as PI3K/mTOR inhibitors
  申请人：ADVENCHEN PHARMACEUTICALS, LLC

  公开号：US10730878B2

  公开（公告）日：2020-08-04

  The present invention relates to the compounds of formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with cancers associated with protein kinases, to their use as medicaments for use in the production of inhibition of mTor, pi3k reducing effects in warm¬blooded animals such as humans.

  本发明涉及式 I 的化合物、其制备工艺、含有它们作为活性成分的药物组合物、治疗与蛋白激酶相关的癌症有关的疾病状态的方法，以及它们作为药剂用于产生抑制 mTor、减少人等温血动物中 pi3k 作用的用途。
• FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
  申请人：ADVENCHEN PHARMACEUTICALS, NANJING LTD.

  公开号：EP3169687B1

  公开（公告）日：2019-01-02
• FUSED QUINOLINE COMPOUNDS AS PI3K/MTOR INHIBITORS
  申请人：Advenchen Pharmaceuticals LLC

  公开号：EP3319602B1

  公开（公告）日：2020-02-05
• FUSED QUINOLINE COMPUNDS AS PI3K/mTOR INHIBITORS
  申请人：Advenchen Pharmaceuticals, LLC

  公开号：US20180201613A1

  公开（公告）日：2018-07-19

  The present invention relates to the compounds of formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with cancers associated with protein kinases, to their use as medicaments for use in the production of inhibition of mTor, pi3k reducing effects in warm¬blooded animals such as humans.